Caris Life Sciences, Inc.
CAI
Positions held
Your positionsCAI isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Caris Life Sciences is positioned well in the biotechnology sector, focusing on precision medicine, which is gaining traction as personalized healthcare becomes more mainstream.
- Revenue increased by 22% compared to the prior quarter, reaching $264 million.
- Gross margin improved to 68.1%, up from 65.4% in the previous quarter.
- Despite recent revenue growth, Caris reported a net income loss of $0.637 million in Q2 2026.
- The company has a high debt-to-equity ratio of 76.454, indicating potential financial risk.
- Operating margin remains low at 10.2%, suggesting challenges in controlling costs.
Fundamentals
| Market cap | $7.77B | Enterprise value | $7.43B | Trailing P/E | 16.27 | Forward P/E | 74.69 |
| PEG | — | Price / book | 13.13 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | 45.4% | Earnings growth | — | Gross margin | 69.8% | Operating margin | 10.2% |
| Profit margin | 10.6% | ROE | 20.1% | ROA | 8.8% | Debt / equity | 0.76 |
| Current ratio | 5.53 | Free cash flow | $63.26M | Analyst recommendation | buy | Mean target | $29.46 |
| 52w high | $33.65 | 52w low | $14.19 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $264M | $216M | $293M | $217M | $181M | — |
| Op margin | 10.2% | 2.4% | 30.2% | 15.1% | -9.9% | — |
| Net income | -$0.6M | -$0.5M | $82.0M | $24.3M | -$71.8M | — |
| Gross margin | 68.1% | 65.4% | 75.4% | 68.0% | 62.7% | — |
| Gross profit | $180M | $141M | $221M | $148M | $114M | — |
| Operating income | $26.9M | $5.3M | $88.4M | $32.6M | -$18.0M | — |
- Revenue +22% vs prior quarter ($264M vs $216M).
- Gross margin 68.1% (was 65.4% prior quarter).
- Operating margin expanded to 10.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $812M | $412M | $306M | $258M |
| Op margin | 5.6% | -62.4% | -104.4% | -122.2% |
| Net income | -$68.1M | -$282M | -$341M | -$321M |
| Gross margin | 66.4% | 43.4% | 29.2% | 31.0% |
| Gross profit | $539M | $179M | $89.3M | $80.0M |
| Operating income | $45.1M | -$257M | -$320M | -$316M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months
2026-09-29 · Caris Life Sciences Unveils the Next Evolution of Liquid Biopsy with Enhanced Caris Assure
2026-09-22 · Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look
2026-09-18 · Are Medical Stocks Lagging Bristol Myers Squibb (BMY) This Year?
2026-09-18 · Caris Life Sciences Stock Jumped 10% Yesterday. Here’s Where Shares Could Go Further in 2026.
2026-09-18 · Caris Life Sciences Insider Sold Shares Worth $12,132,080, According to a Recent SEC Filing
2026-09-16 · Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
2026-09-16 · Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?
2026-09-16 · Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?
2026-09-09 · UBS Initiates Coverage on Caris Life Sciences With Neutral Rating, $28 Price Target
2026-09-06 · Could Caris Life Sciences (CAI) Be 7% Undervalued After Its Lung Cancer Research Update?
Price (daily)
Full chart · RSI · MACD · patterns